Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit ...

Capricor Therapeutics Inc. CAPR) on Monday reported a loss of $25.9 million in its second quarter. On a per-share basis, the ...

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

Cambridge-based Sarepta Therapeutics Inc. stock dropped 1.6 percent in Monday trading. Capricor Therapeutics Inc. fell 13.8 percent and Replimune Group Inc. was down 5.7 percent. Prasad left the ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: ...

At 05:45 a.m. ET, Dow E-minis were up 98 points, or 0.22%, with 7,922 contracts changing hands, S&P 500 E-minis were up 6.25 ...

The law firm of Kirby McInerney LLP reminds investors who purchased Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR) securities to contact Thomas W. Elrod of Kirby McInerney LLP ...

Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.

Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration ...

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...

Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Capricor ...

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.